Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07759674
PHASE4

Relationship Between Metformin Treatment, Anemia, and Erythropoietin Levels in Women With Polycystic Ovary Syndrome in Jordan

Sponsor: Jerash Private University

View on ClinicalTrials.gov

Summary

This prospective longitudinal interventional study aims to evaluate the effects of routine metformin therapy on metabolic, iron-related, erythropoietin, lipid, and hematological parameters in adult women with polycystic ovary syndrome (PCOS). Participants diagnosed with PCOS according to established diagnostic criteria receive routine metformin therapy for six months as part of standard clinical care. Clinical and laboratory assessments are performed at baseline, three months, and six months to evaluate changes in insulin resistance, fasting blood glucose, fasting serum insulin, serum ferritin, serum iron, erythropoietin (EPO), lipid profile, and hematological indices. The study also examines the relationships between metabolic, iron-related, and hematological biomarkers during metformin treatment.

Official title: Effects of Routine Metformin Therapy on Insulin Resistance, Iron Metabolism, Erythropoietin, Lipid Profile, and Hematological Parameters in Jordanian Women With Polycystic Ovary Syndrome: A Prospective Longitudinal Interventional Study

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

25

Start Date

2023-06-01

Completion Date

2023-12-01

Last Updated

2026-08-12

Healthy Volunteers

No

Interventions

DRUG

Metformin

Metformin hydrochloride tablets, 500 mg administered orally twice daily for six months as part of routine clinical management of women with polycystic ovary syndrome (PCOS).

Locations (1)

Ministry of Health Primary Healthcare Centers

Amman, Jordan